NASDAQ:ORGS - Orgenesis Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.12
▼ -0.59 (-21.77%)

This chart shows the closing price for ORGS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Orgenesis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ORGS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ORGS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Orgenesis in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.12.

This chart shows the closing price for ORGS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Orgenesis. This rating has held steady since September 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/16/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/17/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/26/2019BenchmarkInitiated CoverageBuy$9.00 ➝ $9.00Low
12/20/2018Dawson JamesReiterated RatingBuyHigh
12/20/2018Dawson JamesInitiated CoverageBuy ➝ BuyMedium
(Data available from 5/17/2017 forward)

News Sentiment Rating

0.95 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/19/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/18/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/18/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/17/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/16/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/18/2022
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/17/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/17/2022

Current Sentiment

  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Positive

Orgenesis logo
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
Read More

Today's Range

Now: $2.12
Low: $2.10
High: $2.71

50 Day Range

MA: $3.24
Low: $2.71
High: $3.74

52 Week Range

Now: $2.12
Low: $2.10
High: $5.85

Volume

450,998 shs

Average Volume

44,662 shs

Market Capitalization

$52.62 million

P/E Ratio

6.63

Dividend Yield

N/A

Beta

0.9

Frequently Asked Questions

What sell-side analysts currently cover shares of Orgenesis?

The following Wall Street analysts have issued stock ratings on Orgenesis in the last year:
View the latest analyst ratings for ORGS.

What is the current price target for Orgenesis?

0 Wall Street analysts have set twelve-month price targets for Orgenesis in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Orgenesis in the next year.
View the latest price targets for ORGS.

What is the current consensus analyst rating for Orgenesis?

Orgenesis currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ORGS.

How do I contact Orgenesis' investor relations team?

Orgenesis' physical mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company's listed phone number is (480) 659-6404 and its investor relations email address is [email protected] The official website for Orgenesis is www.orgenesis.com. Learn More about contacing Orgenesis investor relations.